British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment

BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven. METHO...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorax 1996-03, Vol.51 (3), p.238-247
Hauptverfasser: Gibson, G J, Prescott, R J, Muers, M F, Middleton, W G, Mitchell, D N, Connolly, C K, Harrison, B D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 247
container_issue 3
container_start_page 238
container_title Thorax
container_volume 51
creator Gibson, G J
Prescott, R J
Muers, M F
Middleton, W G
Mitchell, D N
Connolly, C K
Harrison, B D
description BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven. METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study. RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals. CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.
doi_str_mv 10.1136/thx.51.3.238
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1090632</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78074797</sourcerecordid><originalsourceid>FETCH-LOGICAL-b534t-ad5b0190deb7d0c9993e81ea2400edda179b1f6a54fa33a1a83e8d369b32b24b3</originalsourceid><addsrcrecordid>eNp9kc2LFDEQxYMo6zh68yoElPVij6lOutPxIKyLX7DgYdeDp1CdpHcydHfWJC3Of29khkE9eCqK9-PVxyPkKbANAG9f5-3PTQMbvql5d4-sQLRdxWvV3icrxgSrWi7bh-RRSjvGWAcgz8hZJ6WCWqzIt3fRZ5-29GYbIhpv6HUw3uU9vcZogrch-URTXuz-DXXD4ExONAx0DPMtzS5O1ISYvQmpNAWnOTrMk5vzY_JgwDG5J8e6Jl8_vL-5_FRdffn4-fLiquobLnKFtukZKGZdLy0zSinuOnBYC8actQhS9TC02IgBOUfAruiWt6rndV-Lnq_J24Pv3dJPzpoyOuKo76KfMO51QK__Vma_1bfhhwamWMvrYnB-NIjh--JS1pNPxo0jzi4sScuOSSGVLODzf8BdWOJcjtMgJXDeiRoK9epAmRhSim44rQJM_w5Ml8B0A5rrEljBn_25_gk-JlT0F0cdk8FxiDgbn04YZyCb8rM1eXnA-mn3_4G_AFqGrPA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771338421</pqid></control><display><type>article</type><title>British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Gibson, G J ; Prescott, R J ; Muers, M F ; Middleton, W G ; Mitchell, D N ; Connolly, C K ; Harrison, B D</creator><creatorcontrib>Gibson, G J ; Prescott, R J ; Muers, M F ; Middleton, W G ; Mitchell, D N ; Connolly, C K ; Harrison, B D</creatorcontrib><description>BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven. METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study. RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals. CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thx.51.3.238</identifier><identifier>PMID: 8779124</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ</publisher><subject>Adult ; Biological and medical sciences ; Drug Administration Schedule ; Female ; Follow-Up Studies ; General and cellular metabolism. Vitamins ; Humans ; Lung - diagnostic imaging ; Lung - physiopathology ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Prednisolone - administration &amp; dosage ; Prednisolone - therapeutic use ; Radiography ; Respiratory Function Tests ; Sarcoidosis, Pulmonary - diagnostic imaging ; Sarcoidosis, Pulmonary - drug therapy ; Sarcoidosis, Pulmonary - physiopathology ; Societies, Medical ; Treatment Outcome ; United Kingdom</subject><ispartof>Thorax, 1996-03, Vol.51 (3), p.238-247</ispartof><rights>1996 INIST-CNRS</rights><rights>Copyright BMJ Publishing Group LTD Mar 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b534t-ad5b0190deb7d0c9993e81ea2400edda179b1f6a54fa33a1a83e8d369b32b24b3</citedby><cites>FETCH-LOGICAL-b534t-ad5b0190deb7d0c9993e81ea2400edda179b1f6a54fa33a1a83e8d369b32b24b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090632/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090632/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3017599$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8779124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gibson, G J</creatorcontrib><creatorcontrib>Prescott, R J</creatorcontrib><creatorcontrib>Muers, M F</creatorcontrib><creatorcontrib>Middleton, W G</creatorcontrib><creatorcontrib>Mitchell, D N</creatorcontrib><creatorcontrib>Connolly, C K</creatorcontrib><creatorcontrib>Harrison, B D</creatorcontrib><title>British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment</title><title>Thorax</title><addtitle>Thorax</addtitle><description>BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven. METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study. RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals. CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Lung - diagnostic imaging</subject><subject>Lung - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Prednisolone - administration &amp; dosage</subject><subject>Prednisolone - therapeutic use</subject><subject>Radiography</subject><subject>Respiratory Function Tests</subject><subject>Sarcoidosis, Pulmonary - diagnostic imaging</subject><subject>Sarcoidosis, Pulmonary - drug therapy</subject><subject>Sarcoidosis, Pulmonary - physiopathology</subject><subject>Societies, Medical</subject><subject>Treatment Outcome</subject><subject>United Kingdom</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc2LFDEQxYMo6zh68yoElPVij6lOutPxIKyLX7DgYdeDp1CdpHcydHfWJC3Of29khkE9eCqK9-PVxyPkKbANAG9f5-3PTQMbvql5d4-sQLRdxWvV3icrxgSrWi7bh-RRSjvGWAcgz8hZJ6WCWqzIt3fRZ5-29GYbIhpv6HUw3uU9vcZogrch-URTXuz-DXXD4ExONAx0DPMtzS5O1ISYvQmpNAWnOTrMk5vzY_JgwDG5J8e6Jl8_vL-5_FRdffn4-fLiquobLnKFtukZKGZdLy0zSinuOnBYC8actQhS9TC02IgBOUfAruiWt6rndV-Lnq_J24Pv3dJPzpoyOuKo76KfMO51QK__Vma_1bfhhwamWMvrYnB-NIjh--JS1pNPxo0jzi4sScuOSSGVLODzf8BdWOJcjtMgJXDeiRoK9epAmRhSim44rQJM_w5Ml8B0A5rrEljBn_25_gk-JlT0F0cdk8FxiDgbn04YZyCb8rM1eXnA-mn3_4G_AFqGrPA</recordid><startdate>19960301</startdate><enddate>19960301</enddate><creator>Gibson, G J</creator><creator>Prescott, R J</creator><creator>Muers, M F</creator><creator>Middleton, W G</creator><creator>Mitchell, D N</creator><creator>Connolly, C K</creator><creator>Harrison, B D</creator><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19960301</creationdate><title>British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment</title><author>Gibson, G J ; Prescott, R J ; Muers, M F ; Middleton, W G ; Mitchell, D N ; Connolly, C K ; Harrison, B D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b534t-ad5b0190deb7d0c9993e81ea2400edda179b1f6a54fa33a1a83e8d369b32b24b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Lung - diagnostic imaging</topic><topic>Lung - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Prednisolone - administration &amp; dosage</topic><topic>Prednisolone - therapeutic use</topic><topic>Radiography</topic><topic>Respiratory Function Tests</topic><topic>Sarcoidosis, Pulmonary - diagnostic imaging</topic><topic>Sarcoidosis, Pulmonary - drug therapy</topic><topic>Sarcoidosis, Pulmonary - physiopathology</topic><topic>Societies, Medical</topic><topic>Treatment Outcome</topic><topic>United Kingdom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gibson, G J</creatorcontrib><creatorcontrib>Prescott, R J</creatorcontrib><creatorcontrib>Muers, M F</creatorcontrib><creatorcontrib>Middleton, W G</creatorcontrib><creatorcontrib>Mitchell, D N</creatorcontrib><creatorcontrib>Connolly, C K</creatorcontrib><creatorcontrib>Harrison, B D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gibson, G J</au><au>Prescott, R J</au><au>Muers, M F</au><au>Middleton, W G</au><au>Mitchell, D N</au><au>Connolly, C K</au><au>Harrison, B D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>1996-03-01</date><risdate>1996</risdate><volume>51</volume><issue>3</issue><spage>238</spage><epage>247</epage><pages>238-247</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven. METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study. RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals. CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.</abstract><cop>London</cop><pub>BMJ</pub><pmid>8779124</pmid><doi>10.1136/thx.51.3.238</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0040-6376
ispartof Thorax, 1996-03, Vol.51 (3), p.238-247
issn 0040-6376
1468-3296
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1090632
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Adult
Biological and medical sciences
Drug Administration Schedule
Female
Follow-Up Studies
General and cellular metabolism. Vitamins
Humans
Lung - diagnostic imaging
Lung - physiopathology
Male
Medical sciences
Pharmacology. Drug treatments
Prednisolone - administration & dosage
Prednisolone - therapeutic use
Radiography
Respiratory Function Tests
Sarcoidosis, Pulmonary - diagnostic imaging
Sarcoidosis, Pulmonary - drug therapy
Sarcoidosis, Pulmonary - physiopathology
Societies, Medical
Treatment Outcome
United Kingdom
title British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A41%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=British%20Thoracic%20Society%20Sarcoidosis%20study:%20effects%20of%20long%20term%20corticosteroid%20treatment&rft.jtitle=Thorax&rft.au=Gibson,%20G%20J&rft.date=1996-03-01&rft.volume=51&rft.issue=3&rft.spage=238&rft.epage=247&rft.pages=238-247&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thx.51.3.238&rft_dat=%3Cproquest_pubme%3E78074797%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771338421&rft_id=info:pmid/8779124&rfr_iscdi=true